Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857458 | 0.92 | HSD17B10 (0.32) | FFAR4P2RX7 | |
| SCHEMBL17861556 | 0.88 | ALDH1A1 (0.34) | FFAR4ALDH1A1 | |
| SCHEMBL16322327 | 0.79 | FFAR4 (0.32) | FFAR4ALDH1A1 | |
| SCHEMBL16322326 | 0.79 | FFAR4 (0.32) | FFAR4ALDH1A1 | |
| SCHEMBL16341721 | 0.72 | HTT (0.31) | — | |
| SCHEMBL16321200 | 0.68 | SMN1; SMN2 (0.63) | ALDH1A1 | |
| SCHEMBL16321199 | 0.68 | SMN1; SMN2 (0.63) | ALDH1A1 | |
| SCHEMBL16340842 | 0.66 | CYP3A4 (0.50) | ALDH1A1 | |
| SCHEMBL16340841 | 0.66 | CYP3A4 (0.50) | ALDH1A1 | |
| SCHEMBL17476757 | 0.66 | KMT2A (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | TNNI3, NME4, TNNT2 | FFAR4 3784/4885P2RX7 1595/4885APLNR 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.